Riva-Alendronate Fc 70 mg

RIVA-ALENDRONATE FC 70 MG tablets contain alendronic acid, a medication used to treat osteoporosis and improve bone density. This oral tablet is manufactured by Laboratoire Riva Inc. in Canada.

RIVA-ALENDRONATE FC 70 MG is primarily used to treat osteoporosis in postmenopausal women and to increase bone mass in men with osteoporosis. Alendronic acid works by slowing bone loss, helping to maintain bone strength and reduce the risk of fractures. This medication is often prescribed for individuals who are at high risk of bone fractures due to low bone density.

Common effects of RIVA-ALENDRONATE FC 70 MG may include mild stomach upset, heartburn, or acid reflux. Some users might experience muscle pain, headache, or dizziness. Severe side effects are rare but can include difficulty swallowing, new or worsening heartburn, or jaw problems. Always consult a healthcare provider if you experience any unusual symptoms.

RIVA-ALENDRONATE FC 70 MG should be taken with a full glass of water, and you should remain upright for at least 30 minutes after taking the tablet to prevent irritation. Do not lie down or consume food, beverages, or other medications for at least 30 minutes after taking this medication. Individuals with low calcium levels, kidney problems, or difficulty swallowing should use this medication with caution.

RIVA-ALENDRONATE FC 70 MG may interact with certain medications, including antacids, aspirin, and other nonsteroidal anti-inflammatory drugs (NSAIDs). Alcohol consumption should be limited, as it can increase the risk of stomach irritation. Always inform your healthcare provider about all medications and supplements you are taking to avoid potential interactions.